Zyprexa IM Dosing
The recommended intramuscular dose of olanzapine (Zyprexa) for acute agitation is 10 mg IM, with dose reductions to 5 mg for geriatric patients and 2.5 mg for debilitated patients or those predisposed to hypotension. 1
Standard Adult Dosing
The FDA-approved dosing for IM olanzapine in acute agitation is:
- Initial dose: 10 mg IM (standard adult dose)
- Alternative lower doses: 5 mg or 7.5 mg may be considered when clinical factors warrant
- Repeat dosing: If agitation persists, subsequent doses up to 10 mg may be given, but not more frequently than 2 hours after the initial dose and 4 hours after the second dose
- Maximum daily dose: 30 mg total (e.g., three 10 mg injections given 2-4 hours apart) 1
The 10 mg dose demonstrated superior efficacy in clinical trials, with mean PANSS-EC score reductions of -9.4 at 2 hours compared to -5.5 for 2.5 mg 2. Onset of action occurs within 30 minutes for doses ≥5 mg 2.
Special Population Adjustments
Geriatric patients (≥60 years):
- Reduce to 5 mg IM per injection 1
Debilitated patients or those predisposed to hypotension:
- Reduce to 2.5 mg IM per injection 1
These dose reductions are critical because maximal dosing (three 10 mg doses) is associated with substantial orthostatic hypotension 1. Patients requiring subsequent injections should be assessed for orthostatic hypotension before each additional dose.
Administration Technique
- Route: Intramuscular only - do not give IV or subcutaneously
- Injection technique: Inject slowly, deep into muscle mass
- Reconstitution: Dissolve vial contents with 2.1 mL sterile water to yield 5 mg/mL concentration
- Timing: Use immediately within 1 hour after reconstitution 1
Safety Considerations
Critical warnings:
- Assess orthostatic blood pressure before repeat dosing - do not give additional doses if clinically significant postural hypotension is present 1
- Hypotension was the most frequently reported adverse event in trials 2
- Treatment-emergent parkinsonism occurred in 16.7% with IM haloperidol but 0% with olanzapine 2.5-7.5 mg 2
Comparative safety data from geriatric emergency department studies showed olanzapine had a 15% adverse event rate (15/101 patients), lower than midazolam (53%) and comparable to haloperidol (16%) 3. Notably, no cardiac dysrhythmias or QTc prolongation >500 ms occurred 4.
Transition to Oral Therapy
Once clinically appropriate, transition to oral olanzapine 5-20 mg/day 1. The IM formulation is intended only for acute management of agitation, not maintenance treatment.
Clinical Context
IM olanzapine demonstrated efficacy equivalent to IM haloperidol for acute agitation in schizophrenia and bipolar mania, with superior tolerability regarding extrapyramidal symptoms 4, 2. In real-world Japanese postmarketing surveillance of 999 patients, the 10 mg initial dose was used in 95.6% of cases with favorable safety (TEAEs in only 2.8%) 5.
Common pitfall: Avoid giving doses more frequently than the 2-4 hour intervals specified, as safety beyond these parameters has not been established 1.